Spero Therapeutics Stock Performance
| SPRO Stock | USD 1.19 0.01 0.83% |
The entity has a beta of 0.63, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Spero Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Spero Therapeutics is expected to be smaller as well. At this point, Spero Therapeutics has a negative expected return of -0.19%. Please make sure to validate Spero Therapeutics' coefficient of variation, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if Spero Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Spero Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
1 | Acquisition by Esther Rajavelu of 300000 shares of Spero Therapeutics subject to Rule 16b-3 | 08/30/2024 |
2 | Spero Therapeutics to Present at Upcoming September Investor Conferences | 09/04/2024 |
3 | Discretionary transaction by Gsk Plc of tradable shares of Spero Therapeutics subject to Rule 16b-3 | 09/13/2024 |
4 | Acquisition by Tregoning Kathleen of 35604 shares of Spero Therapeutics at 1.52 subject to Rule 16b-3 | 10/01/2024 |
5 | Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy | 10/02/2024 |
6 | Spero Therapeutics Announces Presentation of SPR719 In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 | 10/16/2024 |
7 | Spero Therapeutics Announces Operational Restructuring and Strategic Workforce Reduction Spero Therapeutics, Inc. made significant announcements on October 29, ... | 10/29/2024 |
8 | Disposition of 23351 shares by Esther Rajavelu of Spero Therapeutics at 1.31 subject to Rule 16b-3 | 11/07/2024 |
9 | Disposition of 17245 shares by Esther Rajavelu of Spero Therapeutics at 1.3 subject to Rule 16b-3 | 11/08/2024 |
10 | Repligen Q3 Earnings and Revenues Beat Estimates | 11/12/2024 |
11 | Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update | 11/14/2024 |
12 | Grifols Board Rejects Brookfields Buyout Offer, Stock Down 8 | 11/20/2024 |
| Begin Period Cash Flow | 109.1 M |
Spero |
Spero Therapeutics Relative Risk vs. Return Landscape
If you would invest 137.00 in Spero Therapeutics on August 23, 2024 and sell it today you would lose (18.00) from holding Spero Therapeutics or give up 13.14% of portfolio value over 90 days. Spero Therapeutics is currently does not generate positive expected returns and assumes 2.5076% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Spero, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Spero Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spero Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Spero Therapeutics, and traders can use it to determine the average amount a Spero Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0754
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SPRO |
Estimated Market Risk
| 2.51 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Spero Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Spero Therapeutics by adding Spero Therapeutics to a well-diversified portfolio.
Spero Therapeutics Fundamentals Growth
Spero Stock prices reflect investors' perceptions of the future prospects and financial health of Spero Therapeutics, and Spero Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spero Stock performance.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | (1.87) % | ||||
| Current Valuation | (6.25 M) | ||||
| Shares Outstanding | 54.52 M | ||||
| Price To Earning | 81.20 X | ||||
| Price To Book | 1.00 X | ||||
| Price To Sales | 0.55 X | ||||
| Revenue | 96.73 M | ||||
| Gross Profit | (42.11 M) | ||||
| EBITDA | 27.15 M | ||||
| Net Income | 22.81 M | ||||
| Cash And Equivalents | 45.4 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 5.54 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.65 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (32.99 M) | ||||
| Earnings Per Share | 0.08 X | ||||
| Market Capitalization | 65.42 M | ||||
| Total Asset | 182.39 M | ||||
| Retained Earnings | (391.07 M) | ||||
| Working Capital | 94.06 M | ||||
| Current Asset | 7.3 M | ||||
| Current Liabilities | 6.04 M | ||||
About Spero Therapeutics Performance
By examining Spero Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Spero Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Spero Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.2 K | -1.2 K | |
| Return On Tangible Assets | 0.13 | 0.13 | |
| Return On Capital Employed | 0.15 | 0.16 | |
| Return On Assets | 0.13 | 0.13 | |
| Return On Equity | 0.21 | 0.22 |
Things to note about Spero Therapeutics performance evaluation
Checking the ongoing alerts about Spero Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Spero Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Spero Therapeutics generated a negative expected return over the last 90 days | |
| Spero Therapeutics may become a speculative penny stock | |
| Spero Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Spero Therapeutics currently holds about 45.4 M in cash with (32.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from zacks.com: Grifols Board Rejects Brookfields Buyout Offer, Stock Down 8 |
- Analyzing Spero Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spero Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Spero Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Spero Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spero Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Spero Therapeutics' stock. These opinions can provide insight into Spero Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.08 | Revenue Per Share 2.223 | Quarterly Revenue Growth 2.754 | Return On Assets 0.1048 |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.